Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
4 today · 14 yesterday · 2 this week
The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.
Original title: “Xenon shares fall following depression trial pause”
The multi-drug partnership with Orbis Medicines—which Novo has backed since the biotech's seed rounds—is focused on cardiometabolic targets, but the technology at the center of the deal could deliver oral weight loss candidates. Obesity rival Eli Lilly has also helped fund Orbis.
Original title: “Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs”
Learn what manufacturing challenges lie ahead, how to equip your team to protect your program from avoidable manufacturing and regulatory setbacks and forge partnerships that can withstand the next five years of industry turbulence.
Original title: “Webinar: Manufacturing in Turbulent Times”
While increases in the interest rate from the Federal Reserve are usually bad for biotech, the sector at this moment is poised to withstand the blow, according to analysts, though earlier stage companies may be left in the lurch.
Original title: “Fed rate hike won’t hold biotech down despite climbing capital costs”
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
Original title: “After Novartis’ devastating M&A losses, long live the executive willing to try”
Novartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.
Original title: “Novartis drops $125M for Sironax’s tech to cross blood-brain barrier”
The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
Original title: “Roche bets up to $1B to advance next-gen bispecifics with Dualitas”
From engineering to science/R&D, these top seven biopharma disciplines each have hundreds, and in one case over 1,000, positions posted on BioSpace.
Original title: “Trending: Top biopharma disciplines with jobs live now”
As biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other locations and functions have also been going strong.
Original title: “Biopharma hiring hotspots: States, disciplines where demand is highest”
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.
Original title: “Novartis to pay $125M for blood-brain barrier crossing platform”
The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
Original title: “Novo looks to Anthropic’s AI models to ‘supercharge’ drug development”